Becton, Dickinson and Company (BD) has introduced the new PIVO Pro Needle-free Blood Collection Device following 510(k) clearance from the US Food and Drug Administration (FDA).

Designed to be compatible with integrated catheters, the new needle-free blood draw technology is said to further enable BD’s ‘One-Stick Hospital Stay’ vision.

The device comes with design enhancements to attain compatibility with integrated and long peripheral IV catheters, including the new Nexiva Closed IV Catheter System with NearPort V Access.

This builds upon PIVO’s existing compatibility with traditional short peripheral IV catheters introduced in 2017.

With the capacity to draw blood samples directly from a patient’s peripheral IV line using PIVO Pro, the new solution integrates the clinical benefits demonstrated by the integrated closed Nexiva Catheter System.

These benefits include reduced catheter complications and longer dwell times.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

BD Medication Delivery Solutions worldwide president Eric Borin said: “The latest innovation to our PIVO portfolio helps expand needle-free blood collection to even more patients and clinicians as we continue to redefine the standard of care through our ‘One-Stick Hospital Stay’ vision.

“This new solution helps to reduce unnecessary and repeat needlesticks in the hospital while elevating clinical outcomes, improving workflow and creating a better experience for clinicians and patients.”

In July 2023, the FDA granted 510(k) clearance for the updated BD Alaris Infusion System.

The approval included the latest hardware advancements for point-of-care units, patient-controlled analgesia pumps, large volume pumps, syringe pumps and respiratory monitoring and auto-identification modules.